The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The BRUIN CLL-313 trial: pirtobrutinib versus BR in previously untreated CLL
In this video, Catherine Coombs, MD, UC Irvine Health, Orange County, CA, briefly comments on the BRUIN CLL-313 trial (NCT05023980), a Phase III randomized study comparing pirtobrutinib to bendamustine plus rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So as far as the BRUIN-313 trial, all I know is what’s contained in the press release, which is it’s a positive study. And this isn’t a surprise to me. I think, you know, BR isn’t exactly what I would have picked for a comparator arm. It’s a little bit outdated by US standards. Obviously, there is still some global use of this regimen, and I would anticipate a lot of the accrual was ex-US...
So as far as the BRUIN-313 trial, all I know is what’s contained in the press release, which is it’s a positive study. And this isn’t a surprise to me. I think, you know, BR isn’t exactly what I would have picked for a comparator arm. It’s a little bit outdated by US standards. Obviously, there is still some global use of this regimen, and I would anticipate a lot of the accrual was ex-US. So I will be interested to see the results, not because I’m curious to see how BR performs. You know, I think we know how well that regimen works, which it kind of works, but not for that long. But to see how lengthy the responses are for patients that are getting pirto in the frontline, does the tolerability hold up, etc. So hopefully we see that at an upcoming Congress.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie, AstraZeneca, BeOne Medicines, Lilly, Genentech, Janssen.
